Technical Guide For Solid Dispersion Development

The number of pipeline drug candidates that are poorly soluble, falling into Developability Classification System (DCS) Class IIa, IIb, and IV, continues to increase. The poorly soluble nature of these compounds leads to poor absorption, poor bioavailability, and increased pharmacokinetic variability. Clinically, these features result in drugs with poor efficacy and safety profiles. Because many of these drugs exist as crystalline materials, the answer may lie in creating an amorphous solid dispersion (ASD) for which spray drying technology is a key part of the manufacturing process. There are many articles on the theory and scientific principles underpinning the benefits of ASD.
Read this article published in Drug Development and Delivery to get the steps involved in the development and manufacturing of an ASD via the spray drying process.

Click here to read article.